| Dr Larry D Deffenbaugh, DO | |
|
3114 Medical Park Dr, Carthage, MO 64836-1211 | |
| (620) 783-2430 | |
| Not Available |
| Full Name | Dr Larry D Deffenbaugh |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 50 Years |
| Location | 3114 Medical Park Dr, Carthage, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447290622 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | R6321 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital Carthage | Carthage, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Clinic Joplin Llc | 0547300196 | 247 |
News Archive
In this post in the Global Health Governance blog, Jenilee Guebert, director of research for the global health diplomacy program and G8 research group at the University of Toronto's Munk School of Global Affairs, writes that, "for the second year in a row, the amount of attention devoted to global health" at the annual G8 summit, which took place at Camp David in Maryland in May, has declined.
Osteros Biomedica Ltd., a joint venture company of Maxwell Biotech Group and MBC Pharma Inc., and formed with the participation of Russian Venture Company announced today that the first cohort of patients has been dosed in a phase 1 study of its drug MBC-11 in patients with cancer-induced bone disease.
Until now, it was thought that multiple brain areas were needed to control sleep and wakefulness. Neuroscientists from Bern have now identified one single control center for the sleep-wake cycle in the brain. The findings are of great importance for finding new sleep therapies.
Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.
› Verified 3 days ago
| Entity Name | Mercy Clinic Joplin Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215264817 PECOS PAC ID: 0547300196 Enrollment ID: O20091218000092 |
News Archive
In this post in the Global Health Governance blog, Jenilee Guebert, director of research for the global health diplomacy program and G8 research group at the University of Toronto's Munk School of Global Affairs, writes that, "for the second year in a row, the amount of attention devoted to global health" at the annual G8 summit, which took place at Camp David in Maryland in May, has declined.
Osteros Biomedica Ltd., a joint venture company of Maxwell Biotech Group and MBC Pharma Inc., and formed with the participation of Russian Venture Company announced today that the first cohort of patients has been dosed in a phase 1 study of its drug MBC-11 in patients with cancer-induced bone disease.
Until now, it was thought that multiple brain areas were needed to control sleep and wakefulness. Neuroscientists from Bern have now identified one single control center for the sleep-wake cycle in the brain. The findings are of great importance for finding new sleep therapies.
Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.
› Verified 3 days ago
| Entity Name | Larry Deffenbaugh Do Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760705925 PECOS PAC ID: 5294870580 Enrollment ID: O20100311000501 |
News Archive
In this post in the Global Health Governance blog, Jenilee Guebert, director of research for the global health diplomacy program and G8 research group at the University of Toronto's Munk School of Global Affairs, writes that, "for the second year in a row, the amount of attention devoted to global health" at the annual G8 summit, which took place at Camp David in Maryland in May, has declined.
Osteros Biomedica Ltd., a joint venture company of Maxwell Biotech Group and MBC Pharma Inc., and formed with the participation of Russian Venture Company announced today that the first cohort of patients has been dosed in a phase 1 study of its drug MBC-11 in patients with cancer-induced bone disease.
Until now, it was thought that multiple brain areas were needed to control sleep and wakefulness. Neuroscientists from Bern have now identified one single control center for the sleep-wake cycle in the brain. The findings are of great importance for finding new sleep therapies.
Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Larry D Deffenbaugh, DO 3114 Medical Park Dr, Carthage, MO 64836-1211 Ph: (620) 783-2430 | Dr Larry D Deffenbaugh, DO 3114 Medical Park Dr, Carthage, MO 64836-1211 Ph: (620) 783-2430 |
News Archive
In this post in the Global Health Governance blog, Jenilee Guebert, director of research for the global health diplomacy program and G8 research group at the University of Toronto's Munk School of Global Affairs, writes that, "for the second year in a row, the amount of attention devoted to global health" at the annual G8 summit, which took place at Camp David in Maryland in May, has declined.
Osteros Biomedica Ltd., a joint venture company of Maxwell Biotech Group and MBC Pharma Inc., and formed with the participation of Russian Venture Company announced today that the first cohort of patients has been dosed in a phase 1 study of its drug MBC-11 in patients with cancer-induced bone disease.
Until now, it was thought that multiple brain areas were needed to control sleep and wakefulness. Neuroscientists from Bern have now identified one single control center for the sleep-wake cycle in the brain. The findings are of great importance for finding new sleep therapies.
Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.
› Verified 3 days ago
Johnny L Venter, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3125 Dr Russell Smith Way, Carthage, MO 64836 Phone: 417-358-8121 | |
Anne E. Winkler, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3125 Dr Russell Smith Way, Carthage, MO 64836 Phone: 417-359-2675 Fax: 417-359-2679 |